Annual Revenue Comparison: Eli Lilly and Company vs ACADIA Pharmaceuticals Inc.

Eli Lilly's Revenue Dominance Over ACADIA: A Decade in Review

__timestampACADIA Pharmaceuticals Inc.Eli Lilly and Company
Wednesday, January 1, 201412000019615600000
Thursday, January 1, 20156100019958700000
Friday, January 1, 20161733100021222100000
Sunday, January 1, 201712490100022871300000
Monday, January 1, 201822380700021493300000
Tuesday, January 1, 201933907600022319500000
Wednesday, January 1, 202044175500024539800000
Friday, January 1, 202148414500028318400000
Saturday, January 1, 202251723500028541400000
Sunday, January 1, 202372643700034124100000
Monday, January 1, 202445042700000
Loading chart...

Unlocking the unknown

A Tale of Two Pharmaceutical Giants: Eli Lilly vs. ACADIA

In the ever-evolving landscape of pharmaceuticals, revenue growth is a key indicator of a company's success. Over the past decade, Eli Lilly and Company has consistently outperformed ACADIA Pharmaceuticals Inc. in terms of annual revenue. From 2014 to 2023, Eli Lilly's revenue surged by approximately 74%, reaching a staggering $34 billion in 2023. In contrast, ACADIA's revenue, while growing impressively by over 600%, still lags behind, peaking at $726 million in the same year.

Revenue Trends and Insights

Eli Lilly's robust growth can be attributed to its diverse portfolio and strategic investments in research and development. Meanwhile, ACADIA's significant percentage increase highlights its potential in niche markets, despite its smaller scale. This comparison underscores the dynamic nature of the pharmaceutical industry, where both established giants and emerging players have unique roles to play.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025